Met Life Investment Management, LLC Arcellx, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 24,981 shares of ACLX stock, worth $1.72 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
24,981
Previous 24,981
-0.0%
Holding current value
$1.72 Million
Previous $1.38 Million
51.38%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding ACLX
# of Institutions
204Shares Held
44.1MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$275 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$268 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$258 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$242 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$169 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.02B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...